- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04654728
Prospective Randomized Study Comparing ePTFE Versus Dacron Graft for Anterior Sector Venous Drainage in Right Lobe Living Donor Liver Transplantation
December 26, 2020 updated by: ATIF TEKIN, Istanbul Medipol University Hospital
Prospective Randomized Study Comparing ePTFE Versus Dacron Graft Donor Liver Transplantation
Living donor liver transplantation (LDLT) using the right lobe (RL) has created a significant increase in graft supply worldwide.
However, it is a technically demanding procedure particularly because of the unique functional anatomic characteristics of hepatic venous drainage [1].
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
In the absence of an adequate drainage of the anterior sector (AS) veins, the consequent venous congestion in the RL graft may result in impaired graft regeneration, immediate liver dysfunction, and graft loss even in a liver graft of adequate size [2].
To overcome this problem, Lee et al. [3] introduced the concept of modified RL graft in which the branches of the middle hepatic vein (MHV) was drained using interposition vascular grafts.
Although, the issue of when and how the MHV branches should be drained has been controversial since then, reconstruction of segment 5 and 8 veins using an interposition graft has become a standard procedure during RL LDLT.
The vascular graft of choice in this procedure has been cryopreserved homologous vein graft, which provides excellent patency with low infection risk.
However, such grafts are often unavailable, particularly in programs where deceased donors are scarce and surgeons must rely on synthetic grafts such as expanded polytetrafluoroethylene (ePTFE) and polyethylene terephthalate (Dacron®).
Since we have developed an "intent-to-drain" policy in our LDLT program, we have been using Dacron grafts exclusively [4].
Although, complications such as early graft thrombosis, graft infection, and hollow viscous migration remain as major concerns, the safety and efficacy of both ePTFE and Dacron grafts in LDLT has been proven [5, 6].
However, to date, none of the previous studies have specifically compared these two different prosthetic materials, addressing graft patency and complication rates in patients undergoing LDLT.
The aim of our study is to compare AS venous outflow reconstruction using ePTFE vs. Dacron grafts for their patency and infection rates and outcomes with respect to graft and patient survival in RL LDLT.
Study Type
Interventional
Enrollment (Anticipated)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: ATIF TEKIN, M.D.
- Phone Number: +905321007771
- Email: dr.atiftekin@gmail.com
Study Contact Backup
- Name: Mahmut Zenciroglu, M.D.
- Phone Number: +905064919779
- Email: mahmutzenciroglu@gmail.com
Study Locations
-
-
-
Istanbul, Turkey, 34214
- Recruiting
- Medipol University Faculty of Medicine
-
Contact:
- ATIF TEKIN, M.D.
- Phone Number: +905321007771
- Email: dr.atiftekin@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Primary Adult Living Donor Liver Transplantation
- Right Lobe graft with anterior sector venous outflow reconstruction -
Exclusion Criteria:
- Right Lobe graft without anterior sector venous outflow reconstruction
- Liver re-transplantation -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ePTFE graft
In this group, anterior sector of the right lobe graft will be reconstructed using ePTFE vascular grafts
|
In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
Other Names:
|
Other: Dacron graft
In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
|
In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Graft patency at 6-month posttransplant
Time Frame: 6 months
|
Graft Patency
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Graft-related complications
Time Frame: One Year
|
Rate of graft infection
|
One Year
|
Graft survival
Time Frame: One year
|
Morbidity
|
One year
|
Patient survival
Time Frame: One Year
|
Mortality
|
One Year
|
Graft regeneration rate
Time Frame: 6 months
|
Graft regeneration
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Murat Dayangac, M.D., Study Chief
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 2, 2020
Primary Completion (Anticipated)
September 24, 2022
Study Completion (Anticipated)
December 30, 2022
Study Registration Dates
First Submitted
November 23, 2020
First Submitted That Met QC Criteria
December 3, 2020
First Posted (Actual)
December 4, 2020
Study Record Updates
Last Update Posted (Actual)
December 29, 2020
Last Update Submitted That Met QC Criteria
December 26, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- Medipol Transplant
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patency and Infection Rates Due to Usage of PTFE vs.Dacron Grafts
-
Implantology InstituteUnknownOsseointegration Failure of Dental Implant Due to Infection | Osseointegration Failure of Dental Implant Prior to Intentional Prosthetic Loading
-
University of MinnesotaAgency for Healthcare Research and Quality (AHRQ)CompletedWound Infection Due to Staphylococcus Aureus | MRSA Infection of Postoperative WoundUnited States
-
Vestre Viken Hospital TrustUniversity of Oslo; University Hospital of North Norway; Helse Sor-OstCompletedUrinary Tract Infection | Infection Due to ESBL Bacteria | Environmental Contamination of ESBL
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Catrine IsehedUmeå UniversityCompletedInflammation | Periodontal Diseases | Mouth Diseases | Bacterial Infections | Peri-implantitis | Infection | Failure of Dental Implant Due to Infection | Bleeding of Subgingival Space | Molecular Sequence VariationSweden
-
University of Campania "Luigi Vanvitelli"Federico II UniversityCompletedPneumonia, Ventilator-Associated | Hospital Acquired Pneumonia | Infection Due to Resistant Bacteria | Infection of Bloodstream | Infectious Disease of Abdomen
-
Al-Azhar UniversityUnknownTreatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella PneumoniaeEgypt
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
-
OMNI Medical Services, LLCOMNI Medical Services IncRecruitingDepression | COVID-19 | Epilepsy | Multiple Sclerosis | Glaucoma | Cancer | Covid19 | Chronic Pain | Parkinson Disease | Inflammatory Bowel Diseases | Hepatitis C | Insomnia | HIV/AIDS | Amyotrophic Lateral Sclerosis | Fibromyalgia | Anxiety | Bipolar Disorder | Seizures | Crohn Disease | Traumatic Brain Injury | Ulcerative Colitis | Sickle... and other conditionsUnited States
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaboratorsRecruitingMitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditionsUnited States, Australia
Clinical Trials on Active Comparator: ePTFE graft
-
University of the Basque Country (UPV/EHU)Geistlich Pharma AGCompleted
-
Vascutek Ltd.Terminated
-
Merit Medical Systems, Inc.CryoLife, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States
-
Mansoura UniversityUnknown
-
Humacyte, Inc.California Institute for Regenerative Medicine (CIRM); CTI Clinical Trial and...CompletedRenal Failure | Hemodialysis | End Stage Renal Disease | Vascular AccessUnited States, Israel, United Kingdom, Portugal, Poland, Germany
-
Tissue GenesisActive, not recruitingLower Limb IschemiaUnited States
-
Angiotech PharmaceuticalsTerminatedHyperplasia | End Stage Renal Failure on DialysisUnited States
-
TiumBio Co., Ltd.RecruitingEndometriosisCzechia, Italy, Russian Federation, Poland, Ukraine
-
Eisai Inc.CompletedAlzheimer's DiseaseUnited States
-
Stanford UniversityRecruitingTreatment Resistant Depression | Bipolar II Disorder, Most Recent Episode Major Depressive | Current Depressive EpisodeUnited States